Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182151 · ClinicalTrials.gov registry record
Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.
A clinical trial, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- 8
- Enrollment target
NCT05182151 is a clinical trial that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 8 participants.
The verdict
NCT05182151 was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's disease (PD). Many individuals with Parkinson's disease experiencing fluctuations in the severity of their movement problems and medication "off" time. "Off" time refers to periods of the day between doses of PD medication when your motor symptoms (e.g., tremor, stiffness, slowness, walking problems, etc.) are worse and interfere with your ability to complete tasks of daily living. The investigational drug, Istradefylline, is an FDA-approved medication to treat motor fluctuations and "off" time in PD. The purpose of this study is to investigate whether people with Parkinson's disease (PD) who are treated with istradefylline (ISD) show improvements in motivation and apathy over a 12-week period. Specifically, we wish to see whether people with PD who are treated with ISD engage in more physical and recreational activities, such as hobbies and other interests.
Interventions
- DRUG Istradefylline 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-29 |
| Est. Completion | 2023-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182151
The ClinicalTrials.gov registry entry for NCT05182151 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Istradefylline 40 mg is the first listed.
NCT05182151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05182151 about?
NCT05182151 is a clinical study titled "Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.". Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's dise...
What is the current status of trial NCT05182151?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2022-07-29. Estimated completion is 2023-12-01.
What interventions are being tested in trial NCT05182151?
The interventions under investigation include: Istradefylline 40 mg (DRUG).
Who is sponsoring clinical trial NCT05182151?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.